Net Loss of Marksans Pharma reported to Rs 4.03 crore in the quarter ended March 2018 as against net loss of Rs 3.22 crore during the previous quarter ended March 2017. Sales rose 7.92% to Rs 199.39 crore in the quarter ended March 2018 as against Rs 184.75 crore during the previous quarter ended March 2017.

For the full year,net profit rose 215.70% to Rs 35.80 crore in the year ended March 2018 as against Rs 11.34 crore during the previous year ended March 2017. Sales rose 18.97% to Rs 912.69 crore in the year ended March 2018 as against Rs 767.16 crore during the previous year ended March 2017.

Powered by Capital Market - Live News

Net profit of Marksans Pharma reported to Rs 4.33 crore in the quarter ended March 2018 as against net loss of Rs 2.44 crore during the previous quarter ended March 2017. Sales rose 60.96% to Rs 86.84 crore in the quarter ended March 2018 as against Rs 53.95 crore during the previous quarter ended March 2017.

For the full year,net profit rose 7.62% to Rs 12.43 crore in the year ended March 2018 as against Rs 11.55 crore during the previous year ended March 2017. Sales rose 36.52% to Rs 294.66 crore in the year ended March 2018 as against Rs 215.84 crore during the previous year ended March 2017.

Powered by Capital Market - Live News

Marksans Pharma announced that the Board of Directors of the Company at its meeting held on 30 May 2018, inter alia, have recommended the final dividend of Rs 0.05 per equity Share (i.e. 5%) , subject to the approval of the shareholders.

Powered by Capital Market - Live News

Marksans Pharma will hold a meeting of the Board of Directors of the Company on 30 May 2018.

Powered by Capital Market - Live News